5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis |
| |
| Authors: | Friedrich G Kapp Anette Sommer Thomas Kiefer Gottfried Dölken Bernard Haendler |
| |
| Institution: | 1. Global Drug Discovery, Bayer HealthCare, Müllerstr. 178, 13342, Berlin, Germany
2. Internal Medicine C (Haematology and Oncology, Transplant Centre), Ernst-Moritz-Arndt-University, Greifswald, Germany
|
| |
| Abstract: | Background Non-small cell lung cancer (NSCLC) is one of the most frequent malignancies and has a high mortality rate due to late detection
and lack of efficient treatments. Identifying novel drug targets for this indication may open the way for new treatment strategies.
Comparison of gene expression profiles of NSCLC and normal adjacent tissue (NAT) allowed to determine that 5-alpha-reductase
type I (SRD5A1) was up-regulated in NSCLC compared to NAT. This raised the question whether SRD5A1 was involved in sustained
proliferation and survival of NSCLC. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
